• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cancer Research and Treatment >Diagnostic Utility of 18F-FDG PECT/CT in Assessment of Post-therapy Remission or Relapse of Lymphoma
【24h】

Diagnostic Utility of 18F-FDG PECT/CT in Assessment of Post-therapy Remission or Relapse of Lymphoma

机译：18F-FDG PECT / CT在评估淋巴瘤治疗后缓解或复发中的诊断价值

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Treatment and prognosis of lymphoma depend on accurate staging and evaluation. Relapsed Lymphomas represent great problem in accurate quick diagnosis that imply appropriate treatment. Aim of the work: To evaluate diagnostic utility of 18F-FDG PECT/CT in assessment of treatment response and identification of disease relapse. Patients and Methods: This prospective study were conducted on 49 consecutive patients with histologically verified lymphoma. They were 27/49 (55.1%) male and 22/49 (44.9%) female aged 37.83±2.29. All patients were subjected to pretreatment as well a follow up clinical, laboratory, CT PET-CT. PET-CT findings were classified as positive and negative according to remission status and relapse. The sensitivity, specificity and accuracy of PET- CT in assessment of the remission status and relapse were calculated and to be confirmed by open or laparoscopic biopsy. Results: PET-CT detected complete regression in 28 patients (57.14%), partial regression in 4 patients (8.16%), stationary course in 2 patients (4.08%), progression / relapse in 15 patients (30.61%). According to PET/CT 9 (23%) patients were true positive, 25 (65%) were true negative and 5 (13%) were false negative with sensitivity, specificity, positive p predictive value and negative predictive value of 95% and 91%, 90% and 98%, respectively. Conclusion: Our results confirm FDG-PET as a valid tool for assessment of treatment response and detection of relapsing lymphoma. We recommended further multicentric prospective studies that incorporates a larger number of patients should be implemented to define the exact relation between certain clinical, pathological, laboratory and PET factors and fate of the disease.
机译：背景：淋巴瘤的治疗和预后取决于准确的分期和评估。复发性淋巴瘤在准确的快速诊断中代表着巨大的问题，需要进行适当的治疗。工作目的：评估18F-FDG PECT / CT在评估治疗反应和确定疾病复发方面的诊断效用。患者与方法：这项前瞻性研究是对49例经组织学证实为淋巴瘤的患者进行的。他们是男性的27/49（55.1％）和女性的22/49（44.9％），年龄为37.83±2.29。所有患者均接受了预处理以及临床，实验室CT PET-CT的随访。根据缓解状态和复发，PET-CT检查结果分为阳性和阴性。计算PET-CT在评估缓解状态和复发中的敏感性，特异性和准确性，并通过开放式或腹腔镜活检确认。结果：PET-CT检测到28例患者完全消退（57.14％），部分消退4例（8.16％），静止过程2例（4.08％），进展/复发15例（30.61％）。根据PET / CT的结果，有9例（23％）为真阳性，25例（65％）为真阴性，5例（13％）为假阴性，敏感性，特异性，p阳性预测值和阴性预测值分别为95％和91 ％，90％和98％。结论：我们的结果证实FDG-PET是评估治疗反应和检测复发性淋巴瘤的有效工具。我们建议进一步进行多中心前瞻性研究，纳入更多患者，以定义某些临床，病理，实验室和PET因素与疾病命运之间的确切关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号